BioXell announces change in management

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Milan, Italy, 7 September 2009 - BioXell S.p.A. (SIX: BXLN) announced
today the termination on the basis of a mutual agreement of the
employment relationship with Bertrand Lehuu, Chief Business Officer,
effective today. His responsibilities will be taken over by the
company's Chief Executive Officer, Niels Ackermann.

"I would like to thank Bertrand Lehuu for his contribution during his
years at BioXell as a member of the Management Team," said Niels
Ackermann, CEO of BioXell. "We wish him all the best for his future
career."

About BioXell
BioXell S.p.A. (SIX: BXLN) is a listed biopharmaceutical company
focused on the discovery and development of drugs that exploit novel
mechanisms of action. The Company is currently focusing its efforts
on the development of its monoclonal antibody BXL1H5 for the
treatment of chronic pain. Following the conclusion of its Vitamin D3
related R&D activities BioXell is looking into a number of strategic
options in line with the demands of its shareholders.

BioXell was founded in 2002 as a spin-out from Roche. In June 2006,
BioXell listed its shares on the main segment of the SIX Swiss
Exchange. The Company is located in Milan, Italy.

More information on BioXell can be found at: www.bioxell.com

For further information, please contact:

BioXell
S.p.A.
Dynamics Group SA
Alvise
Sagramoso
Christophe Lamps
Tel: +39 02 210 49
51
Tel: +41 (0)22 308 62 22
Fax: +39 02 210 49
529
Fax: +41 (0)22 308 62 36
alvise.sagramoso@bioxell.com cla@dynamicsgroup.ch

This press release can be downloaded at www.bioxell.com.
Disclaimer
This press release does not constitute or form part, or all, of any
offer or invitation to sell or issue, or any solicitation of any
offer to purchase or subscribe for, any securities, nor shall part,
or all, of these materials or their distribution form the basis of,
or be relied on in connection with, any contract or investment
decision in relation to any securities. This press release contains
forward-looking statements based on the currently held beliefs and
assumptions of the management of BioXell, which are expressed in good
faith and, in their opinion, reasonable. Forward-looking statements
involve known and unknown risks, uncertainties and other factors,
which may cause the actual results, financial condition, performance,
or achievements of BioXell, or industry results, to differ materially
from the results, financial condition, performance or achievements
expressed or implied by such forward-looking statements. Given these
risks, uncertainties and other factors, recipients of this document
are cautioned not to place undue reliance on these forward-looking
statements. BioXell disclaims any obligation to update these
forward-looking statements to reflect future events or developments.

--- End of Message ---

bioXell S.p.A
via Olgettina 58 Milan Italy

WKN: A0J3MW; ISIN:
IT0004069933 ;
Listed: Main Market in SIX Swiss Exchange;
Copyright © Hugin AS 2009. All rights reserved.